Welcome to our dedicated page for Intra-Cellular Therapies news (Ticker: ITCI), a resource for investors and traders seeking the latest updates and insights on Intra-Cellular Therapies stock.
Intra-Cellular Therapies Inc. (NASDAQ: ITCI) is a biopharmaceutical pioneer developing innovative treatments for central nervous system disorders through its Nobel Prize-inspired intracellular research approach. This comprehensive news hub provides investors and healthcare professionals with essential updates on the company’s clinical advancements, regulatory milestones, and therapeutic developments.
Access real-time updates on ITCI’s neuropsychiatric drug pipeline, including detailed coverage of clinical trial results for conditions like schizophrenia and bipolar depression. Our curated collection features official press releases about FDA communications, research collaborations, and scientific presentations alongside analysis of market-moving developments.
Key content categories include updates on late-stage clinical trials, regulatory submissions for novel CNS treatments, and strategic partnerships advancing neurological research. Users will find critical information about ITCI’s small-molecule therapies and their progress through development phases.
Bookmark this page for streamlined access to verified information about Intra-Cellular Therapies’ groundbreaking work in neuropsychiatry. Check regularly for updates on drug efficacy studies, patent developments, and corporate announcements that impact the future of CNS disorder treatments.
Intra-Cellular Therapies (Nasdaq: ITCI), a biopharmaceutical company specializing in treatments for central nervous system (CNS) disorders, announced that its CEO, Sharon Mates, Ph.D., will present at the Jefferies Global Healthcare Conference. This event is scheduled for June 5, 2024, at 11:00 a.m. ET in New York, NY. A live and archived webcast will be available on the company's website under the Investor Relations section. Viewers are advised to log in 5-10 minutes early to register and install necessary software.
Intra-Cellular Therapies (Nasdaq: ITCI) presented data at the American Society of Clinical Psychopharmacology Annual Meeting, held in Miami from May 28-31, 2024. The data focused on CAPLYTA’s efficacy, safety, and tolerability profiles in treating bipolar I and II disorders, and major depressive disorder (MDD) with mixed features. Key presentations included:
Poster W49: Lumateperone for MDD and Bipolar Disorder with Anxious Distress and Mixed Features.
Poster T40: Lumateperone for MDD and Bipolar Depression with Mixed Features: Symptomatic Efficacy.
Poster T41: Lumateperone for Major Depressive Episodes in MDD and Bipolar Disorders.
CAPLYTA is indicated for schizophrenia and depressive episodes associated with bipolar I or II disorder as monotherapy or adjunctive therapy. The safety profile includes risks such as increased mortality in elderly patients with dementia-related psychosis, suicidal thoughts in young patients, and metabolic changes.
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) will participate in two investor conferences: 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024, and Bank of America Healthcare Conference 2024 on May 16, 2024. The webcasts will be available on the company's website.
Intra-Cellular Therapies reported strong financial results in Q1 2024 with CAPLYTA net product sales of $144.8 million, a 53% increase from the previous year. The company reiterated its 2024 net sales guidance at $645 - $675 million and announced positive Phase 3 results for lumateperone as an adjunctive therapy for major depressive disorder.
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) will host a conference call and webcast on May 7, 2024, to discuss the financial results for the first quarter of 2024. The company focuses on CNS disorder therapeutics. Participants can register online to join the call and access the webcast through the Investor Relations section on the company's website.
FAQ
What is the current stock price of Intra-Cellular Therapies (ITCI)?
What is the market cap of Intra-Cellular Therapies (ITCI)?
